Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 07, 2025 13:24 ET | Source: Herantis Pharma plc

Herantis Pharma presents positive topline data for HER-096 in Phase 1b trial for people living with Parkinson’s disease

Herantis Pharma announces positive topline data for HER-096 in Phase 1b trial for people living with Parkinson’s disease Trial meets all primary and secondary endpoints establishing a strong...
September 09, 2025 15:20 ET | Source: Serina Therapeutics, Inc.

Serina Therapeutics Secures Up to $20 Million to Advance Registrational Trial of SER-252 in Parkinson’s Disease

Transaction structured to provide flexible funding to support Phase 1b registrational clinical study program in advanced Parkinson’s under the 505(b)(2) NDA pathwayEvaluating complementary funding...
September 08, 2025 16:05 ET | Source: NeuroOne Medical Technologies Corporation

NeuroOne® to Participate in Sidoti Small-Cap Conference on September 17th and 18th, 2025

EDEN PRAIRIE, Minn., Sept. 08, 2025 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving...
September 04, 2025 02:50 ET | Source: Karolinska Development AB (publ)

Karolinska Developments portföljbolag Umecrine Cognition publicerar data som visar på ihållande effekt av golexanolon i preklinisk Parkinsonmodell

STOCKHOLM, 4 september 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) meddelar att portföljbolaget Umecrine Cognition presenterar data som visar att läkemedelskandidaten golexanolon ger...
September 04, 2025 02:50 ET | Source: Karolinska Development AB (publ)

Karolinska Development’s portfolio company Umecrine Cognition publishes data showing sustained effect of golexanolone in a Parkinson’s disease model

STOCKHOLM – September 4, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company Umecrine Cognition has presented data showing that its drug candidate...
August 25, 2025 16:15 ET | Source: Serina Therapeutics, Inc.

Serina Therapeutics Announces FDA Feedback Supports Registrational Trial Design of SER-252 in Advanced Parkinson’s Disease under 505(b)(2) NDA Pathway

- U.S. IND filing planned for Q4 2025 with U.S. enrollment expected to start in Q1 2026 - Patient dosing expected to begin in Australia in Q4 2025 HUNTSVILLE, AL, Aug. 25, 2025 (GLOBE NEWSWIRE)...
August 14, 2025 09:02 ET | Source: Herantis Pharma plc

Last patient visit completed on schedule in Phase 1b clinical trial of HER-096 for Parkinson’s disease

Patient visits are now complete in the final cohort of Phase 1b trial, consisting of Parkinson’s disease patients receiving 300 mg doses of HER-096 or placebo twice weekly over a four-week...
May 13, 2025 02:05 ET | Source: Herantis Pharma plc

First patients dosed in final cohort of Phase 1b clinical trial of HER-096 for Parkinson’s disease

Herantis Pharma Plc – Press release First patients dosed in final cohort of Phase 1b clinical trial of HER-096 for Parkinson’s disease HER-096 is a first-in-class agent in development for the...
April 29, 2025 08:30 ET | Source: FYR Bio

FYR Enters Know-How Agreement with Mayo Clinic to Collaborate on Blood-Based Biomarker Solutions for Parkinson’s Disease

FYR anounced a collaboration with Mayo Clinic to advance the use of blood-based biomarkers in Parkinson’s disease (PD) research and clinical applications.
April 15, 2025 03:00 ET | Source: AKAMPION

1ST Biotherapeutics Joins The Michael J. Fox Foundation’s LITE Program to Advance LRRK2-Based Parkinson’s Disease Research

Focus on the discovery of next-generation LRRK2 inhibitors to unlock novel biological mechanisms of action and advance new treatment options YONGIN, South Korea, April 15, 2025 – 1ST Biotherapeutics,...